SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals shines on entering into joint venture agreement with Orbicular

21 Apr 2016 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 602.95, up by 31.50 points or 5.51% from its previous closing of Rs. 571.45 on the BSE.

The scrip opened at Rs. 579.20 and has touched a high and low of Rs. 604.00 and Rs. 577.95 respectively. So far 15638 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 791.70 on 15-Jul-2015 and a 52 week low of Rs. 443.00 on 28-Apr-2015.

Last one week high and low of the scrip stood at Rs. 604.00 and Rs. 515.55 respectively. The current market cap of the company is Rs. 11375.99 crore.

The promoters holding in the company stood at 74.13 % while Institutions and Non-Institutions held 12.92 % and 12.96 % respectively.

Alembic Pharmaceuticals (APL) has entered into joint venture agreement (JVA) with Orbicular Pharmaceutical Technologies (Orbicular) to develop, manufacture and commercialize dermatology products for worldwide markets. Orbicular has capabilities in developing dermatology products with a fully-equipped and staffed research laboratory in Hyderabad and has a pipeline of products under various stages of development. Manufacturing facility will be established in Aleor Dermaceuticals (Aleor) to enable worldwide registrations.

APL and Orbicular will own 60% and 40% of the equity capital of Aleor when the transaction is completed. The JVA has standard terms including transfer of employees, financing and borrowing, management functioning, restriction on transfer of shares, non-compete, non-solicitation and termination events and consequences.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.

 

Alembic Pharma Share Price

759.00 -25.95 (-3.31%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×